Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?

References

• . Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7(1):3–14
   PubMed Web of Science ®Google Scholar
• . Jacobsen PK. Preventing end stage renal disease in diabetic patients—genetic aspect (part I). J Renin Angiotensin Aldosterone Syst. 2005;6(1):1–14
   PubMed Web of Science ®Google Scholar
• . Roig E, Perez-Villa F, Morales M,. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21(1):53–57
   PubMed Web of Science ®Google Scholar
• . van de Wal RM, Plokker HW, Lok DJ,. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol. 2006;106(3):367–372
   PubMed Web of Science ®Google Scholar
• . Tomiyama H, Kushiro T, Abeta H,. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension. 1994;23(4):450–455
   PubMed Web of Science ®Google Scholar
• . Tolerability and quality of life in ARB-treated patients. Am J Manag Care. 2005;11( suppl 13):S392–S394
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Mallion JM, Boutelant S, Chabaux P,. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997;2(4):179–184
   PubMedGoogle Scholar
• . Black HR, Graff A, Shute D,. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997;11(8):483–489
   PubMed Web of Science ®Google Scholar
• . Holwerda NJ, Fogari R, Angeli P,. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996;14(9):1147–1151
   PubMed Web of Science ®Google Scholar
• . Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J, Tou CK; AMAZE. Antihypertensive efficacy of candesartan-lisinopril in combination vs up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich). 2004;6(9):485–493
   PubMedGoogle Scholar
• . Oparil S, Yarows SA, Patel S, Zhang J, Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet. 2007;370(9593):1126–1127
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002;4(6):420–423
   PubMedGoogle Scholar
• . Chobanian AV, Bakris GL, Black HR,; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Mann JF, Gerstein HC, Yi QL,. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003;14(3):641–647
   PubMed Web of Science ®Google Scholar
• . de Zeeuw D, Remuzzi G, Parving HH,. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–2320
   PubMed Web of Science ®Google Scholar
• . Lea J, Greene T, Hebert L,. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165(8):947–953
   PubMedGoogle Scholar
• . Gerstein HC, Mann JF, Yi Q,; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Jurkovitz CT, Pergola PE; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167(11):1122–1129
   PubMedGoogle Scholar
• . Eijkelkamp WB, Zhang Z, Remuzzi G,. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–1546
   PubMed Web of Science ®Google Scholar
• . Rahman M, Pressel S, Davis BR,. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(8):936–946
   PubMedGoogle Scholar
• . Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin. 2008;24(5):1285–1293
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Fassi A, Ilieva AP,; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Hollenberg NK, Parving HH, Viberti G,. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921–1926
   PubMed Web of Science ®Google Scholar
• . Casas JP, Chua W, Loukogeorgakis S,. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–2033
   PubMed Web of Science ®Google Scholar
• . Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372(9638):511–512
   PubMed Web of Science ®Google Scholar
• . Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;4:CD006257
   Google Scholar
• . Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008;21(8):922–929
   PubMed Web of Science ®Google Scholar
• . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROSHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259
   PubMed Web of Science ®Google Scholar
• . ; DREAM Trial InvestigatorsDagenais GR, Gerstein HC, Holman R,. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31(5):1007–1014
   PubMed Web of Science ®Google Scholar
• . Balamuthusamy S, Srinivasan L, Verma M,. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008;155(5):791–805
   PubMed Web of Science ®Google Scholar
• . Haller H, Viberti GC, Mimran A,. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403–408
   PubMed Web of Science ®Google Scholar
• . ONTARGET Investigators; Yusuf S, Teo KK, Pogue J,. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M,; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med. 2006;45(4):193–198
   PubMed Web of Science ®Google Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI Investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008;23(10):3174–3183
   PubMed Web of Science ®Google Scholar
• . Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364–369
   PubMed Web of Science ®Google Scholar
• . Maione A, Nicolucci A, Craig JC,; LIRICO Study Group. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial. J Nephrol. 2007;20(6):646–655
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005
   Google Scholar
• . Braunwald E, Domanski MJ, Fowler SE,; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–2068
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Gerstein H, Hoogwerf B,; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286(15):1882–1885
   PubMed Web of Science ®Google Scholar
• . Kjeldsen SE, Julius S, Mancia G,; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens. 2006;24(7):1405–1412
   PubMed Web of Science ®Google Scholar
• . , DREAM Trial InvestigatorsBosch J, Yusuf S, Gerstein HC,. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–1562
   PubMed Web of Science ®Google Scholar
• . Barzilay JI, Davis BR, Cutler JA,; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191–2201
   PubMed Web of Science ®Google Scholar
• . Black HR, Davis B, Barzilay J,; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31(2):353–360
   PubMed Web of Science ®Google Scholar
• . Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–207
   PubMed Web of Science ®Google Scholar
• . Califf RM, Boolell M, Haffner SM,; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J. 2008;156(4):623–632
   PubMed Web of Science ®Google Scholar
• . Clasen R, Schupp M, Foryst-Ludwig A,. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension. 2005;46(1):137–143
   PubMed Web of Science ®Google Scholar
• . Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens. 2008;21(8):852–859
   PubMed Web of Science ®Google Scholar
• . Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens. 2008;26(5):973–980
   PubMed Web of Science ®Google Scholar
• . Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007;7(3):191–199
   PubMedGoogle Scholar
• . Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006;29(5):1167–1169
   PubMed Web of Science ®Google Scholar
• . Bakris G, Molitch M, Hewkin A,; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29(12):2592–2597
   PubMed Web of Science ®Google Scholar
• . Bakris G, Molitch M, Zhou Q,. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008;3(1):18–25
   PubMedGoogle Scholar
• . Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual care setting. J Manag Care Pharm. 2003;9(5):424–129
   PubMedGoogle Scholar
• . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857–1863
   PubMed Web of Science ®Google Scholar
• . Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252–1256
   PubMed Web of Science ®Google Scholar
• . Wright Jr JT, Bakris G, Greene T,; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR,; Collaborate Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D,; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Makino H, Haneda M, Babazono T,; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1577–1578
   PubMed Web of Science ®Google Scholar
• . Lacourcière Y, Bélanger A, Godin C,. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58(2):762–769
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Bain SC, Bouter P,; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351(19):1952–1961
   PubMed Web of Science ®Google Scholar